Metronomically-administered MTAs have been clinically evaluated in NSCLC in combination with targeted agents such as Vascular Endothelial Growth Factor (VEGF) or EGFR inhibitors30, 31, but never with anti-Akt compounds. Here, VEGFA is linked to non-small cell lung carcinoma.